Watchlists Portfolios Alerts Sign in Get started

Menu

Innate Pharma S.A. IPHA

Full chart Compare

Set alert

1.44 USD +0.04 (+2.86%)

At closeNov 6, 2026, 4:00 PM EST

1.46 +0.02 +1.39%

After hours · Nov 6, 4:00 PM ET

1.40 Day range 1.48

1.17 52-week range 2.71

YTD: -17.71%
1 year: -20.00%

News

2 days ago seekingalpha.com Innate Pharma S.A. (IPHA) Q3 2026 Earnings Call Transcript Innate Pharma S.A. (IPHA) Q3 2026 Earnings Call Transcript
3 days ago marketbeat.com Innate Pharma Q3 Earnings Call Highlights Innate Pharma NASDAQ: IPHA said it has initiated a Phase 3 study of its lymphoma drug lacutamab and expects to present Phase 1 data for its experimental cancer treatment IPH4502 on Nov. 18, as the…
4 days ago benzinga.com Innate Pharma 9M Revenue €3.4M Vs €2.3M YoY, Cash €96.8M; CFO Frédéric Lombard To Step Down December 31 Phase 1 dose-escalation data for Nectin-4 ADC IPH4502 to be presented at ENA 2026 on November 18, followed by a webcast and in-person eventLacutamab, partnered with Sobi, progressing toward first…